TLTavexia Lifecare539519Quarterly results

Board gives in-principle nod to raise up to Rs. 68 crore for 60% Meyonex stake; H1 shows a loss

Tavexia Lifecare's board met on 04 November 2026 and approved unaudited results for the quarter and half year ended 30 September 2026, reviewed by Devam & Associates LLP.

By ScoutQuest · Wed 4 Nov 2026, 9:30 PM IST · 3 min read

H1 Revenue from Operations

39.20 lakh against 317.53 lakh a year earlier

H1 Profit / Loss

loss of (73.75) lakh against a profit of 125.53 lakh

Approved Fund Raise

up to ₹68 crore to finance the proposed acquisition of 60% of Meyonex Pharmaceuticals

The board meeting was held on Wednesday, 04 November 2026, from 06.30 P.M. to 09.20 P.M.

What the board approved

• Unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, and took on record the Limited Review Report of Devam & Associates LLP, Chartered Accountants, on those results.
• Considered and took on record the Statement of deviation(s) or variation(s) in the use of proceeds from the objects stated in the rights issue offer document.
• Approved a change of Registrar & Transfer Agent from Niche Technologies Pvt. Ltd to Skyline Financial Services Pvt. Ltd. Niche will continue as RTA until the data transition, shifting of electronic connectivity and related procedures are completed; the effective date is to be intimated separately.

Fund raising plan

• The board considered raising funds through a preferential issue of securities, a rights issue of equity shares, or any other permissible mode of issuance, for an aggregate amount not exceeding ₹68 crore (Rupees Sixty-Eight Crores Only), in one or more trenches.
• It accorded its in-principle approval and authorised the Executive Directors to appoint consultants, professionals, intermediaries, valuers and other experts to evaluate and recommend the most appropriate mode and type of securities.
• The money is intended to finance the proposed acquisition of 60% of the equity share capital of Meyonex Pharmaceuticals Limited, as approved by the board at its meeting on 07 October 2026.
• The final decision on mode, structure, terms and conditions is to be considered and approved at a subsequent board meeting, subject to statutory and regulatory requirements.

Financial results (standalone, unaudited)

• Revenue from operations for the half year ended 30 September 2026 was 39.20 lakh, against 317.53 lakh in the same half of the previous year.
• Profit for the half year was a loss of (73.75) lakh, against a profit of 125.53 lakh a year earlier.
• For the quarter, net sales were 15.80 lakh against 195.98 lakh, and the loss for the period was (51.40) lakh against a profit of 60.40 lakh.
• For the full year ended 31 March 2026 (audited), total income was 422.22 lakh and profit 16.52 lakh.
• Total assets stood at 4,864.57 lakh as at 30 September 2026.
• Paid-up equity share capital was 3,836.01 lakh, with a face value of Rs. 1.00 per share; basic and diluted earnings per share were (0.02) for the half year and (0.01) for the quarter.

What this means for a retail holder

• The half year's numbers show a loss and much lower revenue than the same period a year earlier, which is the weak part of this update.
• The fund raise, if completed, could bring in up to ₹68 crore, but the mode, pricing and terms are still open and the board's approval is in-principle only.
• The proposed purchase of 60% of Meyonex Pharmaceuticals Limited is the stated use of the money; the acquisition itself was approved by the board on 07 October 2026.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.

About ScoutQuest · Logos provided by Logo.dev